UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Iovance Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.000041666 per share (Title of Class of Securities)

> 462260 10 0 (CUSIP Number)

February 20, 2024 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 \Box Rule 13d-1(b)

 \boxtimes Rule 13d-1(c)

 \Box Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 462260 10 0

00011	NO. 402200	10 0				
1	NAMES OF REPORTING PERSONS					
	Perceptive A					
2		IE A b) [PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) □ (U) L				
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
		5	SOLE VOTING POWER			
NI	JMBER OF		0			
5	SHARES	6	SHARED VOTING POWER			
	EFICIALLY WNED BY		19,221,743			
	EACH	7	SOLE DISPOSITIVE POWER			
	EPORTING PERSON		0			
	WITH:	8	SHARED DISPOSITIVE POWER			
			19,221,743			
9	AGGREGA	TE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	19,221,743					
10		DX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	_	OF (CLASS REPRESENTED BY AMOUNT IN ROW 9			
	(00/					
12	6.9% TYPE OF R	EPC	ORTING PERSON (SEE INSTRUCTIONS)			
	IA					

CUSIP No. 462260 10 0

00011	110. 402200					
1	NAMES OF REPORTING PERSONS					
	Joseph Edel	man				
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) 🗆 ((b) [
3	SEC USE ONLY					
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION					
	United State	es of	America			
		5	SOLE VOTING POWER			
NU	JMBER OF		0			
	SHARES	6	SHARED VOTING POWER			
	IEFICIALLY WNED BY		19,221,743			
0	EACH	7	SOLE DISPOSITIVE POWER			
RI	REPORTING		SOLE DISCOSITIVE TO WER			
	PERSON		0			
	WITH:		SHARED DISPOSITIVE POWER			
	L G G D E G L		19,221,743			
9	AGGREGA	TE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	19,221,743					
10)X I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
	-					
11	PERCENT	OF 0	CLASS REPRESENTED BY AMOUNT IN ROW 9			
	6.00/					
12	6.9% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
14		CEFU	SKIINO I ERSON (SEE INSTRUCTIONS)			
	IN					

CUSIP No. 462260 10 0

1	NAMES OF REPORTING PERSONS					
	Descention Life Coloneers Mantee E and Ltd					
2	Perceptive Life Sciences Master Fund, Ltd. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					
2		b) [
)				
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Cayman Isla	ands 5	SOLE VOTING POWER			
		3	SOLE VOTINGTOWER			
NI	JMBER OF		0			
	SHARES	6	SHARED VOTING POWER			
	NEFICIALLY					
0	WNED BY	_	19,221,743			
R	EACH EPORTING	7	SOLE DISPOSITIVE POWER			
	PERSON		0			
	WITH:	8	SHARED DISPOSITIVE POWER			
			19,221,743			
9	AGGREGA	TE /	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	19,221,743					
10	19,221,745 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
	(00/					
12	6.9% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
14	I IFE OF REFORTING FERSON (SEE INSTRUCTIONS)					
	СО					
LI						

Item 1(a).	Name of Issuer:						
	Iovance Biotherapeutics, Inc. (the "Issuer")						
Item 1(b).	Address of Issuer's Principal Executive Offices:						
	825 Industrial Road, Suite 400, San Carlos, California 94070						
Item 2(a).	Names of Persons Filing:						
The nan	ames of the persons filing this report (collectively, the "Reporting Persons") are:						
	Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")						
Item 2(b).	Address of Principal Business Office or, if None, Residence:						
The add	lress of the principal business office of each of the Reporting Persons is:						
	51 Astor Place, 10th Floor New York, NY 10003						
Item 2(c).	<u>Citizenship</u> :						
	Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation						
Item 2(d).	Title of Class of Securities:						
	Common Stock, par value \$0.000041666 ("Common Stock")						
Item 2(e).	CUSIP Number:						
	462260 10 0						
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:						
	Not applicable.						
Item 4.	<u>Ownership</u> .						
	The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 279,307,043 outstanding shares of Common Stock, as reported in the Issuer's Annual Report on Form 10-K filed on February 28, 2024.						

The Master Fund directly holds 19,221,743 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

Item 5. <u>Ownership of Five Percent or Less of a Class</u>.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. <u>Ownership of More than Five Percent on Behalf of Another Person</u>.

Not applicable.

 Item 7.
 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

- Item 8.
 Identification and Classification of Members of the Group.

 Not applicable.
 Not applicable.
- Item 9. <u>Notice of Dissolution of Group</u>.

Not applicable.

Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: March 1, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: <u>/s/ Joseph Edelman</u> Name: Joseph Edelman Title: Managing Member

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: March 1, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman Name: Joseph Edelman

Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member